Like multiple myeloma, trogocytosis-mediated surface antigen loss poses a significant barrier to effective CAR T cell therapy of MSLN-positive solid tumors, as expression pattern of MSLN is naturally heterogeneous and trogocytosis may additionally downregulate its expression [14]. Here, MSLN is linked to AL amyloidosis.